Please login to the form below
oral semaglutide
This page shows the latest oral semaglutide news and features for those working in and with pharma, biotech and healthcare.
Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial
Also within Novo’s roster is an oral formulation of semaglutide – marketed under the Rybelsus brand name – that is authorised for the treatment of type 2 diabetes. ... More participants in the semaglutide-treated group also achieved a weight
Latest news
-
Novo Nordisk launches late-stage study in Alzheimer’s disease
Study will evaluate oral semaglutide in neurodegenerative disease. Novo Nordisk is planning to enter a late-stage development programme with the launch of a phase 3a study of oral semaglutide in ... Novo Nordisk markets oral semaglutide as Ryblesus in
-
Novo Nordisk set to acquire Emisphere Technology for $1.8bn
Following the acquisition deal completion, Novo will pick up Emisphere’s drug delivery technology – Eligen SNAC – which it uses in its oral diabetes drug Rybelsus (oral semaglutide). ... Since then, the oral diabetes drug has been approved in
-
Lilly’s Trulicity scores CV reduction indication in the US
The new MACE approval could help Lilly in its fight for market share with other GLP-1 agonists, including Novo Nordisk’s once-weekly drug Ozempic (semaglutide). ... Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto
-
New drugs drive Novo Nordisk despite insulin price pressures
This included a boost from GLP-1 agonist Ozempic (semaglutide) which has been climbing solidly since its launch, as demand increases for the drug. ... Novo also reported sales of DKK50m for its recently launched oral semaglutide product Rybelsus in
-
Givlaari, Rybelsus lead crowded CHMP recommendations
Joining Givlaari with a positive recommendation was Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide.
Novo Nordisk launches late-stage study in Alzheimer’s disease
Novo Nordisk set to acquire Emisphere Technology for $1.8bn
Lilly’s Trulicity scores CV reduction indication in the US
Givlaari, Rybelsus lead crowded CHMP recommendations
More from news
Approximately 3 fully matching, plus 20 partially matching documents found.
Latest Intelligence
-
On our best behaviour
Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.
-
Cortellis Drugs to Watch in 2020 report
Allergan’s Ubrelvy is the only other oral CGRP antagonist approved for acute migraine, which entered the market ahead of rimegepant. ... 7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide
-
Oral biologics delivery still elusive
Novo Nordisk is also working with another specialist on oral delivery for protein drugs - Emisphere Technologies - that has applied its Eligen technology to develop an oral version of semaglutide, a ... rarely as once a quarter for example, which makes
On our best behaviour
Cortellis Drugs to Watch in 2020 report
Oral biologics delivery still elusive
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
